Center for AIDS Research, Program in Molecular Medicine, Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Biotech II, 373, Plantation Street, Worcester. MA 01605, USA1
The Wohl Virion Center, Department of Immunology and Molecular Pathology, The Windeyer Institute for Medical Sciences, University College London, 46 Cleveland Street, London W1P 6DB, UK2
Author for correspondence: Paul Clapham. Fax +1 508 856 4075. e-mail paul.clapham{at}umassmed.edu
![]() |
Abstract |
---|
![]() |
Introduction |
---|
Lentiviruses are enveloped viruses that acquire a lipid membrane while budding from the membranes of an infected cell. After budding, the Gag proteins of the virus core are processed by the virion protease to form a mature infectious particle. The resulting cone-shaped core contains the viral genomic RNA that is delivered into a new cell to start a fresh cycle of replication. The first events that initiate infection are: (1) attachment of the virus particle to the cell surface and (2) fusion of the virus and cell membranes to deliver the virion core into the cell cytoplasm (Fig. 1A). For HIV, attachment and fusion are mediated by the interaction of virion glycoprotein spikes with cell surface receptors.
|
|
|
![]() |
HIV envelope structure and attachment of HIV particles to cell surfaces |
---|
CD4 is the major receptor for HIV and SIV (Sattentau et al., 1988 ). Each monomer of gp120 contains a binding site for CD4. Engagement of one CD4 molecule by a single gp120 in the trimeric spike is sufficient to induce conformational changes in all three glycoprotein monomers of the trimer (Salzwedel & Berger, 2000
). HIV type 1 (HIV-1) strains adapted for replication in CD4+ T-cell lines (T-cell line-adapted, TCLA) have an affinity for CD4 up to 50 times higher than envelopes of primary isolates (Moore et al., 1992
). Despite CD4 affinities that are often low, primary viruses are still dependent on CD4 for fusion; however, the importance of CD4 for attachment to cells is questionable. Furthermore, while some cell types targeted by HIV in vivo express high levels of CD4 (for example, T-cells), others, including macrophages and dendritic cells (DCs), express barely detectable amounts. In these situations, HIV may attach to cells by CD4-independent interactions involving sugar groups on the envelope glycoprotein with other sugars or lectin-like domains on cell surface receptors, such as the mannose-specific macrophage endocytosis receptor (Larkin et al., 1989
). Table 1
lists cell surface molecules identified to interact with gp120. A cell surface protein (DC-SIGN) identified by its capacity to bind gp120 with high affinity (Curtis et al., 1992
) is expressed on certain DC populations (Geijtenbeek et al., 2000
). A closely related receptor (DC-SIGNR) expressed on endothelial cells binds HIV in a similar manner (Pohlmann et al., 2001
). Gp120 also binds the glycolipid galactocerebroside (Gal-C) and its sulphated derivative, sulphatide (Fantini et al., 1993
; Harouse et al., 1991
). These molecules are expressed on neurons and glia in the brain (Harouse et al., 1991
), colon epithelial cell lines (Fantini et al., 1993
) and, importantly, on macrophages (Seddiki et al., 1994
). Gal-C binds gp120 with a high affinity, similar to the binding affinity of monomeric gp120 for CD4. Gal-C supports suboptimal entry of particular HIV-1 strains without CD4, although infection requires a coreceptor (Delezay et al., 1997
). Mondor et al. (1998)
have shown that HIV virions attach to HeLa cells via an interaction between gp120 and the glycosaminoglycan heparan sulphate. This interaction can be demonstrated for X4 and R5X4 viruses but is less efficient for R5 virus envelopes, since it is mediated mainly by positively charged V3 loops interacting with negative sulphate groups on glycosaminoglycans (Moulard et al., 2000
).
|
Although HIV may attach to cells via a number of distinct interactions, fusion will not occur until sufficient CD4 and coreceptor molecules are recruited to trigger formation of a fusion pore. Thus, direct and early interactions with CD4 are likely to be the most efficient infection process with the fastest kinetics.
![]() |
Fusion mechanism |
---|
Several glycoprotein spikes form a ring and cooperate in the induction of a fusion pore. For influenza virus, three to six HA trimers are required (Danieli et al., 1996 ). Fusion proceeds from initial curvature of target and virion membranes, following insertion of the fusion peptide, to a short-lived hemifusion stage where only the outer lipid bilayers are fused and, finally, form a flickering pore that stabilizes and expands. Low pH-treated influenza virions usually carry HA1s that appear to be completely disorganized. This disordered state may prevent HA1 from physically hindering the two membranes approaching each other. The fate of gp120, CD4 and coreceptors following gp41 activation is not known. Neither is it clear if gp120 or the receptors play a role in establishing the ring of envelope spikes around the fusion pore or have roles in uncoating events immediately after fusion, as suggested by Chackerian et al. (1997)
.
![]() |
The major receptor, CD4 |
---|
CD4 is a ligand for MHC class II molecules interacting with the 2 subunit. It is expressed predominantly on T-helper cells acting as an accessory receptor in the cellular immune response. Its role is to increase the avidity between helper T-cells and MHC class II+ antigen-presenting cells, forming part of a ternary complex with the T-cell receptor (TCR) in antigen recognition. CD4MHC class II interactions also have roles in cell adhesion, enabling other receptor/ligands to contact.
CD4 is a member of the immunoglobulin superfamily and has four extracellular immunoglobulin-like domains (D1 to membrane proximal D4), a TM region and the cytoplasmic tail that associates with the kinase p56lck. The extracellular domain of CD4 extends 120 , the distance required to span the length of the TCR and interact with MHC class II molecules (Janeway, 1992
). CD4 is also expressed on cell types that do not express a TCR, such as monocytes, macrophages and DCs, all of which can be infected by HIV. The role of CD4 on these cells is not well understood; however, CD4 is a receptor for IL-16, a cytokine with chemoattractant activity for CD4+ lymphocytes, monocytes and eosinophils (Cruikshank et al., 1998
).
Binding site on CD4 for gp120
The interaction between CD4 and gp120 is conserved among all primate lentiviruses. The site on CD4 that interacts with gp120 has been mapped by mutagenesis and the structure of a gp120CD4 complex reported (Kwong et al., 1998 ). The CD4 site that contacts gp120 forms a charged ridge on the N- terminal domain furthest from the cell membrane. This site is part of the CDR2-like region that corresponds to the second of three complementarity-determining regions (equivalent to the antigen-binding site on antibody molecules). F43 and the positive R59 residues in this region make multiple contacts with gp120 residues, including negatively charged D368, E370 and hydrophobic W427. The F43 side chain penetrates a hole on gp120 (Fig. 4A
). About 63% of gp120CD4 contacts are made by CD4 residues 4048 (Kwong et al., 1998
). The contact gp120 residues are derived from several discontinuous sequences and include conserved amino acids where the backbone of the polypeptide chain, rather than amino acid side chains, contacts CD4. Binding of gp120 to CD4 causes rearrangement of the gp120 core (Myszka et al., 2000
) and movement of variable loops resulting in formation and/or exposure of a site that binds a coreceptor. The crystals determined by Kwong et al. (1998)
reveal the structure of gp120 and CD4 complexed together; however, the native gp120 structure prior to CD4 binding remains less clear.
|
Binding site on CD4 for MHC class II molecules
The sites on CD4 that interact with MHC class II molecules are complex and encompass a larger surface area compared to the gp120-binding site (reviewed by Ravichandran et al., 1996 ). Amino acids clustered along one side of CD4 domain D1 in CDR1 and CDR3 as well as domain D2 residues are involved in interaction with MHC class II molecules (Moebius et al., 1993
). Evidence indicates that the CDR2 region on the opposite face of CD4 also binds MHC class II (Huang et al., 1997
; Moebius et al., 1993
) and may be involved in interactions that allow hetero-oligomers to form for augmentation of T-cell activation signals (Huang et al., 1997
). Additional evidence suggests a direct association between CD4 and the TCR via the membrane proximal D3 and D4 domains of CD4 (Vignali et al., 1996
).
IL-16
IL-16 was reported to form homodimers that then interact with the membrane-proximal D4 domain on dimeric CD4 (Liu et al., 1999b ). The ability of peptides derived from the D4 domain of CD4 to block IL-16-induced activation is consistent with domain D4 as the IL-16-binding site (Liu et al., 1999b
).
Human herpes virus-7 (HHV-7) exploits CD4 as a receptor
HHV-7 uses CD4 as a receptor for entry into cells and is inhibited by soluble gp120 as well as by CD4 MAbs (Lusso et al., 1994 ). However, CD4 transfection did not confer HHV-7 sensitivity for all cell lines (Yasukawa et al., 1997
), perhaps indicating that HHV-7 requires a coreceptor for infection. If a coreceptor is required, it is not one of the major HIV coreceptors, CCR5 or CXCR4. Neither is needed for HHV-7 infection (Yasukawa et al., 1999
).
![]() |
Coreceptors |
---|
E. A. Berger and colleagues cloned the first HIV coreceptor, CXCR4 (termed fusin) (Feng et al., 1996 ). Coexpression of CXCR4 with CD4 on mouse cells conferred fusion by SI or T-tropic (but not NSI/M-tropic) HIV-1 strains. Several groups reported CCR5 as the coreceptor for NSI viruses (Alkhatib et al., 1996
; Deng et al., 1996
; Dragic et al., 1996
). CCR5 and CXCR4 are the major HIV-1 coreceptors and all strains can use one (R5 and X4 viruses) or both (R5X4 viruses) to enter CD4+ cells. R5 viruses are predominantly transmitted and persist throughout infection. Viruses that exploit CXCR4 emerge late in disease and can be isolated from up to 50% of AIDS cases. Both CCR5 and CXCR4 are members of the 7TM chemokine receptor family. More than a dozen other 7TM receptors have been shown to act as coreceptors on CD4+ cell lines for particular HIV-1 strains. These coreceptors are also chemokine receptors or are closely related orphan receptors. Currently, there is little evidence to suggest that coreceptors other than CCR5 and CXCR4 are used significantly in vivo.
The pattern of coreceptors used by SIV and HIV-2 is different from HIV-1, as expected (Clapham et al., 1991 ). SIV uses CCR5 but CXCR4 is rarely used (Meister et al., 2001
). SIV strains predominantly exploited in the rhesus macaque (MAC) or cynomolgus animal models, such as African green monkeys (AGM), all use CCR5, as do primary isolates from sooty mangabey monkeys (SMM) (Chen et al., 1998a
). Several SIV strains have been shown to use CXCR4 on cell lines in vitro. In most cases, infection was insubstantial and its significance unclear (Owen et al., 2000
; Schols & De Clercq, 1998
). A switch from CCR5- to CXCR4-use associated with disease progression has not been reported in SIV animal models. T-tropic and M-tropic SIVMAC strains, however, are apparent. These variants differ in the way that CCR5 is exploited as a coreceptor (Edinger et al., 1997
) and in their capacity to exploit low levels of surface CD4 (Bannert et al., 2000
). SIVMAC, SIVSMM and SIVAGM strains often use other coreceptors in addition to CCR5, including GPR15/Bob, CXCR6/Bonzo and GPR1 (reviewed by Clapham & Weiss, 1997
). Furthermore, the majority of red-capped mangabeys in Gabon are homozygous for a 24 bp deletion in their CCR5 gene and harbour an SIV strain that uses CCR2b and STRL-33 but not CCR5 (Chen et al., 1998b
).
GPR15 and CXCR6/Bonzo are used less frequently by HIV-1, while GPR1 is rarely exploited. Unlike the closely related SIVMAC/SIVSMM group viruses, HIV-2 variants that use CXCR4 do evolve in vivo, probably (as for HIV-1) during the later stages of disease. A minority of HIV-2 strains appear to use CXCR4 exclusively (Guillon et al., 1998 ; Reeves et al., 1999
); however, most primary HIV-2 isolates use a much broader range of coreceptors compared to HIV-1 (Bron et al., 1997
; McKnight et al., 1998
; Morner et al., 1999
). Coreceptors used by HIV-2 in the asymptomatic stage of disease are less clear, since virus loads are often very low and isolates are difficult to culture. R5 HIV-2 strains have been reported (Morner et al., 1999
; Reeves et al., 1999
); however, it is not certain whether such strains predominate during the asymptomatic phase and are preferentially transmitted over broadly tropic viruses. Table 2
lists 7TM receptors identified as coreceptors for HIV and SIV strains in vitro.
|
Chemokine receptors form rods in the membrane with a central pore surrounded by the 7TM regions. Bacterial rhodopsin is the only high resolution 7TM structure that has been resolved (Palczewski et al., 2000 ). Such proteins have four domains exposed on the cell surface: the N terminus and three extracellular loops (E1, E2 and E3). Coreceptors take up different conformations on cell surfaces and on different cell types (Baribaud et al., 2001
; Lee et al., 1999
), influencing their ability to support HIV infection. Such conformations may result from the formation of dimers, as reported for CCR5 (Lapham et al., 1999
) or with heterologous chemokine receptors (Mellado et al., 1999
). Associations may also occur with other cell surface molecules, as reported for CCR5 and CD4 (Wu et al., 1996
; Xiao et al., 1999
). Coreceptor sites involved in HIV entry are centred on the N terminus and E2. Mutagenesis studies showed the N terminus of CCR5 is important for coreceptor activity for HIV-1 R5 viruses (Hill et al., 1998
). R5 strains, however, differ in their use of CCR5, as highlighted by the variation in their capacity to infect cells expressing different chimeric human/mouse CCR5 receptors (Picard et al., 1997a
). MAbs that bind the N terminus of CCR5 are most efficient at inhibiting gp120 binding, while E2-specific MAbs are potent inhibitors of fusion and infection (Lee et al., 1999
; Olson et al., 1999
; Wu et al., 1997a
). For SIVMAC, both M-tropic and T-tropic strains use CCR5; however, the former require the N terminus of CCR5, while E2 is crucial for T-tropic SIV strains (Edinger et al., 1997
). It is unclear if there are CCR5-using HIV-1 strains with the properties of T-tropic SIV strains.
For X4 strains, E2 is critical. Deletion of the N terminus of CXCR4 affects some but not all strains (Picard et al., 1997b ), although, when present, participates in binding gp120 (Doranz et al., 1999
). Chimeric coreceptors support X4 virus entry providing E2 is present (Lu et al., 1997
); however, Brelot et al. (1999)
showed that X4 strains vary in their use of CXCR4 E2 with different isolates dependent on distinct E2 residues for activity.
Electrostatic charge interactions are also likely to enhance gp120coreceptor interactions. The N terminus of CCR5 (and often other coreceptors) is negatively charged due to three acidic amino acids and four (potentially) sulphated tyrosines, which are important for coreceptor function (Farzan et al., 1998 ). These negative residues may aid interactions with positive amino acids in and around the bridging sheet on gp120 (Kwong et al., 1998
). Moreover, the V3 loops of X4 strains are positively charged, while E2 of CXCR4 contains five negative residues and these oppositely charged faces may interact, as suggested by Platt et al. (2001)
. Mutagenesis of all five acidic residues does not eliminate HIV infection (Wang et al., 1998
). Thus negatively charged residues at the N terminus of CCR5 and in E2 of CXCR4 may enhance their use by electrostatic interactions with R5 and X4 strains, respectively; however, they may not determine the specificity of the interaction.
The coreceptor-binding site on gp120 involves the conserved bridging-sheet that lies between the protruding V1/V2 and V3 loops, as well as some residues in V3 itself (Kwong et al., 1998 ). Antibodies to both regions block gp120coreceptor interactions (Trkola et al., 1996
; Wu et al., 1996
). The V3 loop has long been known as a determinant of tropism and now coreceptor usage. Positive residues in V3 that confer an SI phenotype correlate with the use of CXCR4. The role of the V1/V2 loops in the coreceptor interaction is less clear, since an HIV-1 mutant with deleted V1/V2 loops was infectious (Cao et al., 1997
), while recombinant gp120 deleted for V1/V2 bound coreceptors (Wu et al., 1996
). However, when present, V1/V2 loops influence tropism (Koito et al., 1994
; Westervelt et al., 199
1) and coreceptors used (Cho et al., 1998
; Ross & Cullen, 1998
). Sites in the V1/V2 loops, the bridging-sheet and the V3 loop may contribute to at least two specific interactions with coreceptors centred on the N terminus and E2. A high affinity interaction at both sites may not be needed to trigger infection and may explain why the specificity of the coreceptor interaction can be predominantly mapped to either the N terminus or E2. In summary, diverse virus strains vary in the sites and specific amino acids of coreceptors that they exploit for recognition and triggering fusion. The capacity of HIV to vary the Env and coreceptor residues involved in their interaction will be a major mechanism of immune evasion.
Chemokine binding to chemokine receptors
Chemokines are chemoattractant proteins with roles in immune development, inflammation, immunity, embryogenesis and development. Chemokines are 70120 residue polypeptides with a common folding pattern that forms an -helix underlying three anti-parallel
-strands and a less-structured N terminus. The first N-terminal loop carries receptor-binding specificities and, once bound, the N terminus itself is thought to interact with a second receptor site to induce receptor activation and signalling. As for gp120, both the N terminus and the E2 of chemokine receptors are implicated in chemokine binding. The gp120- and chemokine-binding sites overlap but can be separated by mutagenesis. For detailed descriptions of chemokine and chemokine receptor structure and function, see the review by Rojo et al. (1999)
.
![]() |
Does HIV signal through CD4 or coreceptors? |
---|
Signalling per se is not needed for coreceptors to function for virus entry, since the pertussis toxin blocks signal induction but not HIV infection on CD4+ cell lines (Aramori et al., 1997 ). Truncation of the CCR5 cytoplasmic region or mutation of the DRY motif both block signal transduction but do not effect the capacity of CCR5 to act as a coreceptor (Gosling et al., 1997
). Despite the observations of J. Corbeil and colleagues, signalling by newly synthesized envelopes will be minimized by several mechanisms (Vpu- and Nef-induced) that downregulate CD4. Loss of CD4 will prevent efficient Envcoreceptor interactions and signalling during late stages of replication. Finally, shed gp120 may interact with cell surface receptors on uninfected cells and induce signals; however, it is not known whether sufficient concentrations of shed gp120 are present in vivo.
![]() |
Cell tropism of HIV in immune and nonimmune tissues |
---|
Whether DCs are infected has been controversial. Blood DCs form two distinct populations: CD11c+ myeloid and CD11c- plasmacytoid. Both populations express CD4, CCR5 and CXCR4 and support at least some level of HIV replication in vitro (Patterson et al., 2001 ). Their sensitivity to infection and extent of replication depends on their stage of maturation and phenotype (Bakri et al., 2001
; Granelli-Piperno et al., 1998
; Patterson et al., 1999
). Blood plasmacytoid DCs are more sensitive to both HIV R5 and X4 viruses than myeloid DCs (Patterson et al., 2001
). Immature myeloid dendritic cells were reported to selectively support replication by R5 viruses (Granelli-Piperno et al., 1998
; Reece et al., 1998
; Zaitseva et al., 1997
). More mature cells are permissive to R5 and X4 virus entry; however, replication blocks prior to (Granelli-Piperno et al., 1998
) and after (Bakri et al., 2001
) provirus integration are described. Immature DCs, such as Langerhans cells at mucosal membranes, may be the first cells encountered by transmitting HIV. Such maturing cells potentially carry HIV either as DC-SIGN-trapped virus (Geijtenbeek et al., 2000
; Masurier et al., 1998
) or as infected cells to lymph nodes, where association with T-cells provides a potent medium for the rapid amplification of progeny virus.
Chemokines also influence the types of cells that become infected (Cocchi et al., 1995 ). Several CD4+CCR5+ T-cell clones from uninfected and nonprogressing HIV-1+ individuals were resistant to infection due (at least in part) to endogenously produced
-chemokines (Saha et al., 1998
; Vyakarnam et al., 2001
). T-cell clones from AIDS patients were substantially more sensitive to infection by R5 viruses, consistent with an increasing colonization of CD4+CCR5+ T-cells as disease progresses. Along mucosal membranes, there is extensive stromal cell-derived factor 1 (SDF-1) expression and downregulation of CXCR4 on T-lymphocytes (Agace et al., 2000
). Langerhans cells taken from under the skin express little surface CXCR4, whereas, on culture, high concentrations of CXCR4 held internally in vesicles are rapidly expressed (Zaitseva et al., 1997
). These observations may explain the restricted transmission of X4 viruses across mucosal membranes and why DCs in vitro and away from the SDF-1-rich environment of mucosa support at least the early entry stages of X4 virus replication. Another explanation is needed to explain selective transmission of R5 viruses directly into the blood (Wilkinson et al., 1998
). Thus, soluble factors such as chemokines in the tissue milieu or produced endogenously by target cells have a major influence on tropism.
In nonimmune tissues and organs, resident-specialized macrophages carry the virus load; for example, in the liver, HIV antigens are detected in Küppfer cells. The brain is colonized by HIV-1 early in infection and eventually results in dementia or related pathology in up to 30% of AIDS cases. The brain is physically isolated from the blood by the bloodbrain barrier, a system of tight, gap junctions between endothelial cells in blood capillaries. HIV is probably carried into the brain by infected monocytes, macrophages or activated T-cells. The main brain cell types infected are perivascular macrophages and microglia (reviewed by Gabuzda & Wang, 2000 ). Astrocytes do not express CD4 but may be occasionally infected in neonates (Saito et al., 1994
). Whether HIV-1 adapts to use brain-expressed coreceptors for replication in brain cells is unclear. Neurotropic and neurovirulent SIV variants have been isolated from infected macaques (Zink et al., 1998
). However, it is not known if equivalent variants are involved in HIV-1 brain infection. It is also controversial whether CXCR4-using viruses colonize the brain when they emerge late in disease and the vast majority of virus isolates and envelope sequences from brain tissue indicate that R5 viruses predominate. Recently, Gorry et al. (2001)
reported isolation of M-tropic R5X4 and X4 strains from the brain tissue of dementia patients. Whether such CXCR4-using strains are implicated in brain pathogenesis is not known and controversial. However, shed gp120 from X4 viruses has been shown to induce apoptosis of neurons (reviewed by Gabuzda & Wang, 2000
). The majority of HIV-1 isolates, including R5 and X4 strains, from blood infect both primary microglial cells and macrophages in vitro (Ghorpade et al., 1998
; He et al., 1997
; Hibbitts et al., 1999
; Shieh et al., 1998
). R5 isolates that replicate more efficiently in microglial cultures have been selected in vitro (Shieh et al., 2000
). Enhanced replication in cultured microglia was conferred by mutations in V1, an envelope region associated with coreceptor use. Specific amino acids at particular sites in the V3 loop (or motifs) have also been associated with envelopes in the brain (Power et al., 1994
). The significance of such motifs is highly controversial but could be associated with the use of alternative brain-encoded coreceptors or with the differential use of CCR5.
![]() |
Significance of coreceptors for transmission, replication and pathogenesis in vivo |
---|
Coreceptor and chemokine polymorphisms
Individuals who are homozygous for a 32 bp deletion (32) in the CCR5 gene are greatly protected from infection whether infection is via sex (Dean et al., 1996
), blood contact (Wilkinson et al., 1998
) or from mother-to-child transmission (Philpott et al., 1999
). The 32 bp deletion results in a premature stop codon and a truncated CCR5 protein that fails to reach the cell surface (Benkirane et al., 1997
). Homozygotes are therefore effectively CCR5-. The protection conferred by
32 CCR5 homozygosity indicates that SI/X4 strains are rarely transmitted, although a small number of HIV+
32 CCR5 homozygotes has been reported. Where tested, these individuals carry viruses that use CXCR4 rather than alternative coreceptors (Michael et al., 1998
). Individuals heterozygous for
32 CCR5 are not protected from infection (Huang et al., 1996
) but survive longer (Dean et al., 1996
). These individuals express lower levels of CCR5 (Wu et al., 1997b
), partly due to a halved CCR5 gene dosage but also because the
32 CCR5 protein interacts with full-length CCR5 in the secretory pathway and retains it there (Benkirane et al., 1997
).
Other human CCR5 polymorphisms include a single change (m303) in the CCR5 gene reported in one family (Quillent et al., 1998 ). m303 causes a premature stop codon that prevents the expression of CCR5. PBMCs from one affected family member who also carried a
32 CCR5 gene (m303/
32 CCR5) were resistant to infection by HIV-1 R5 strains. Several other CCR5 single nucleotide polymorphisms (SNPs) result in amino acid substitutions that interfere with
-chemokine binding and/or coreceptor activity (Carrington et al., 1999
; Howard et al., 1999
). The influence of these rare SNPs on HIV in vivo is not known.
Several polymorphic alleles and SNPs in the CCR5 gene promoter region have been identified (Martin et al., 1998b ; McDermott et al., 1998
). One allele (CCR5 P1, characterized by a pattern of 10 specific bases at particular sites) has been shown to accelerate disease progression in homozygous individuals (Martin et al., 1998b
).
A polymorphism in CCR2b that results in a V64I change in a TM domain slows disease progression. CCR2b V64I has no effect on sexual transmission (Smith et al., 1997 ), although a protective effect on mother-to-child transmission was reported (Mangano et al., 2000
). The V64I change does affect the capacity of CCR2b to act as a coreceptor or signal in response to chemokines (Lee et al., 1998
). Protection may be due to another CCR5 promoter polymorphism (-1835) linked to V64I in the adjacent CCR2b gene. The -1835 polymorphism unlinked to CCR2b V64I is rare and, to date, studies disagree on whether it protects or accelerates (Martin et al., 1998b
; Mummidi et al., 1998
). Mellado et al. (1999)
reported that CCR2b V64I, but not wild-type receptors, formed heterodimers with CXCR4 when costimulated by monocyte chemotactic protein 1 (MCP-1) or SDF-1. Such heterodimers may reduce CXCR4 available for HIV infection and thus could explain CCR2b V64I protection.
CXCR4 is indispensable to mammals. In mice, both CXCR4 (Ma et al., 1998 ; Zou et al., 1998
) and SDF-1 (Ma et al., 1998
) knockouts are lethal. So far, only three rare CXCR4 polymorphisms have been reported that are not linked to pathogenesis (Cohen et al., 1998
; Martin et al., 1998a
). A polymorphism in SDF-1 (the CXCR4 ligand) gene was reported as protective (Winkler et al., 1998
). However, other studies showed a faster disease rate (Mummidi et al., 1998
; van Rij et al., 1998
) or a more rapid decline in CD4 cell numbers (Balotta et al., 1999
). This G to A mutation is located in the 3' noncoding region of SDF-1 mRNA and may influence mRNA stability. Two SNPs in the promoter of the RANTES gene (-471 and -96) also slow disease (Gonzalez et al., 2001
; McDermott et al., 2000
), while one study found an effect on transmission risk (McDermott et al., 2000
). G at -96 led to an increase in RANTES expression providing an explanation for protection (Liu et al., 1999a
). Two SNPs in the first intron of macrophage inflammatory protein 1
(MIP-1
) were also reported to influence disease progression (Gonzalez et al., 2001
). Together, these observations provide evidence that
-chemokines act protectively in vivo. Table 3
summarizes the known polymorphisms in HIV receptors and their ligands that influence the course of HIV infection (reviewed by Carrington et al., 1999
).
|
32 CCR5 homozygotes may also be protected from blood transfer that bypasses the mucosa (Wilkinson et al., 1998
). This observation suggests that there are restrictions to X4 viruses beyond the mucosa and that an incoming virus may need to establish infection at particular site(s) for transmission to be successful. Perhaps a critical tissue or site is permissive for R5 strains but not X4 viruses. Again, observations by Harouse et al. (1999)
that gut lymphoid tissue in macaques supports extensive replication by R5 but not X4 SIV/HIV viruses provide a precedent.
Suppression of X4 strains?
R5 virus replication and variation would be expected to generate variants that can use CXCR4 in a short period of time. Yet, SI/X4 viruses apparently do not always evolve in vivo, can be isolated from only about 50% of AIDS patients and infrequently from HIV-1 subgroup C-infected individuals (Tscherning et al., 1998 ). X4 viruses are not isolated from SIVMAC-infected rhesus macaques, even though some SIV strains can use CXCR4 in vitro (Owen et al., 2000
). It is not known if undetectable levels of CXCR4-using viruses are always present. Regardless, the mechanisms that prevent X4 viruses from predominating in vivo are not understood. Whatever the nature of the restriction, it breaks down and/or is breached during the later stages of disease when CXCR4-using viruses emerge in HIV-1-infected individuals. Valentin et al. (1998)
described how IL-4 downregulates CCR5 while upregulating CXCR4 and enhancing HIV expression. Thus, IL-4 may select for X4 viruses and against R5 strains, a possibility supported by the observation that HIV+ individuals carrying a polymorphism in the IL-4 gene promoter that increases expression were more likely to harbour X4 viruses (Nakayama et al., 2000
).
Two early studies suggested that SI variants present in the acute phase were later suppressed in favour of NSI viruses at seroconversion (Cornelissen et al., 1995 ; Lathey et al., 1997
) and speculated that SI suppression was due to an immune-mediated mechanism (Lathey et al., 1997
). However, primary X4 viruses are as resistant to neutralizing antibodies as R5 strains, while a role for T-cell immunity is difficult to envisage, since T-cell epitopes on the envelope glycoprotein are few and unlikely to distinguish between R5 and X4 strains (reviewed by Michael & Moore, 1999
). The current consensus strongly favours infrequent transmission of CXCR4-using strains and their emergence only late in disease at the peak of virus diversity (Shankarappa et al., 1999
). If X4 strains are frequently present at low levels in infected individuals, new therapies aimed at CCR5 may provide X4 viruses with a selective advantage.
The role of other coreceptors
The extent to which HIV-1 exploits coreceptors other than CCR5 or CXCR4 in vivo is thought to be minimal (Zhang & Moore, 1999 ). The growing number of different 7TM receptors that support HIV and SIV infection of cell lines in vitro therefore does not accurately predict coreceptor usage in vivo. High-level expression of alternative coreceptors out of context on cell lines seems to deliver them to the cell surface in an active form that can confer virus entry. Factors in vivo that may prevent many of the same alternative coreceptors from functioning (as envisaged for CXCR4) are not known. Recent evidence implicates CXCR6/Bonzo for HIV-1 infection of some T-cells (Sharron et al., 2000
) and CCR8 for thymocytes (Lee et al., 2000
). Furthermore, one or more unidentified coreceptors frequently support HIV-2 and SIV infection of primary T-cells and macrophages in vitro (Chen et al., 1998a
; Simmons et al., 2000
; Sol et al., 1997
; Zhang et al., 2000
). Despite these observations, there is no evidence yet to indicate that coreceptors other than CCR5 or CXCR4 significantly influence HIV or SIV replication in vivo.
![]() |
CD4-independent infection |
---|
![]() |
Therapies targeted at HIV entry |
---|
CD4
Intervention of the interaction between CD4 and the HIV envelope is an attractive therapeutic approach, since all HIV and SIV strains bind CD4, while infection without CD4 is probably insignificant in vivo. Therapies based on soluble forms of CD4 were excellent in vitro inhibitors of TCLA HIV-1 strains (Clapham et al., 1989 ) but failed to influence HIV replication in vivo (Schooley et al., 1990
). The sensitivity of TCLA viruses was due to the capacity of soluble CD4 to tear gp120 off virions (Moore et al., 1990
). Primary isolates of HIV-1 (R5 or X4 viruses) were substantially more resistant to soluble CD4 (Daar et al., 1990
), partly because they had a lower affinity for CD4 but also because gp120 was more stably attached to virions (Moore et al., 1992
). New strategies will come from the reported structure of gp120CD4 complexes (Kwong et al., 1998
). For instance, a cavity at the surface of gp120 was revealed that accommodates the phenyl ring of F43 on CD4. Agents designed to block this cavity may interfere with the interaction between gp120 and CD4 and resulting conformational changes.
IL-16
Anti-HIV strategies based on IL-16 have been proposed (Baier & Kurth, 1997 ). IL-16 blocks HIV-1 infection in vitro by mechanisms that include, for example, inhibition of HIV promoter activity (Zhou et al., 1997
), although inhibition of virus entry into macrophages was reported (Truong et al., 1999
). In vivo, IL-16 serum levels increase following HIV-1 infection but drop sharply during the late stages of disease (Amiel et al., 1999
). T-cell clones derived from long-term nonprogressors produce elevated levels of IL-16 along with
-chemokines and the unidentified CD8 antiviral factor (Scala et al., 1997
). Therapeutic approaches that replenish IL-16 include gene therapy strategies where stem cells are engineered to constitutively produce IL-16 (Zhou et al., 1997
) or simply by exogenous administration (Viglianti et al., 1997
). IL-16, however, has potent proinflammatory effects and may be toxic in vivo (Viglianti et al., 1997
). No clinical trials have been reported yet.
Sulphated sugars
Various sulphated sugars block HIV infection in vitro, including heparin (Ito et al., 1987 ), dextran sulphate (Mitsuya et al., 1988
) and curdlan sulphate (Kaneko et al., 1990
). Such agents (heparin, for example) block infection by interacting with sites on gp120, including the V3 loop, while others, such as dextran sulphate, also prevent gp120 from binding CD4 (Harrop et al., 1994
). These agents are not specific for HIV and also block other retroviruses that use different receptors (McClure et al., 1992
). Initial clinical trials with such agents have not reported major influences on virus load or patient health. One study did report reductions in viraemia during and following intraperitoneal administration of dextran-2-sulphate. The mechanism of action, however, is unclear and stimulation of macrophages per se rather than inhibition of HIV entry may be a factor (Shaunak et al., 1998
). Regardless, sulphated sugars are neither potent nor specific inhibitors of HIV replication in vivo and it is unlikely that they will be used widely in therapies.
gp41
An exciting approach aims to block conformational changes in the envelope that lead to fusion. Peptides derived from the leucine zipper-like domain and the membrane proximal -helix of gp41 are efficient inhibitors of infection in vitro. Peptides derived from either region are thought to block complexing of the
-helix and leucine zipper and thus inhibit fusion. One peptide, T-20, corresponding to the TM-proximal
-helix is effective in vivo (Kilby et al., 1998
) and used as a salvage therapy for patients carrying HIV strains resistant to current inhibitors. It is unlikely that peptides like T-20 will be generally exploited for therapy since they cannot be administered orally and are expensive to prepare. Crystal structures of the complexed gp41 trimers consisting of the leucine zippers and
-helices have identified a hydrophobic cavity between the helices (Chan et al., 1998
), providing an opportunity to design small molecules that specifically target and interfere with complex formation and therefore virus fusion (Zhou et al., 2000
).
Coreceptors
The identification of HIV coreceptors has provided an exciting new therapeutic opportunity. CCR5 is an excellent target for therapy since individuals homozygous for the 32 bp deletion in CCR5 are effectively CCR5- but healthy. Agents that specifically target CCR5 and block its natural receptor activity should therefore be safe. Moreover, CCR5 antagonists can be potent inhibitors of R5 virus replication in vitro. We reported that a form of RANTES modified at the N terminus (amino-oxy-pentane-RANTES, AOP-RANTES) potently inhibited infection by R5 strains of HIV (Simmons et al., 1997 ). The potency of AOP-RANTES was due to its capacity to induce CCR5 internalization and retention in endosomes, a property that effectively removed CCR5 from the cell surface (Mack et al., 1998
). Small organic molecules (8001000 kDa) that are inexpensive to manufacture and can be taken orally are the best options to target coreceptors. Such small molecules have been successfully used to target 7TM receptors for treating several diseases such as asthma (Kelloway, 1997
). The first reported small molecule antagonist of CCR5 (TAK-779) was a potent inhibitor of R5 strains in vitro (Baba et al., 1999
). Another CCR5 antagonist (SCH 351125) with improved bioavailability that efficiently blocked R5 virus replication in SCID-hu Thy/Liv mice has been reported (Strizki et al., 2001
). AMD3100, a bicyclam derivative, binds CXCR4 and blocks X4 viruses (Donzella et al., 1998
). At least some of these agents are already in clinical trials and their success in treating HIV+ patients should be known in the next 12 years.
![]() |
Acknowledgments |
---|
![]() |
References |
---|
Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M. & Berger, E. A. (1996). CC CKR5: a RANTES, MIP-1, MIP-1
receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958.[Abstract]
Alkhatib, G., Liao, F., Berger, E. A., Farber, J. M. & Peden, K. W. (1997). A new SIV co-receptor, STRL33. Nature 388, 238.[Medline]
Amiel, C., Darcissac, E., Truong, M. J., Dewulf, J., Loyens, M., Mouton, Y., Capron, A. & Bahr, G. M. (1999). Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. Journal of Infectious Diseases 179, 83-91.[Medline]
Aramori, I., Ferguson, S. S., Bieniasz, P. D., Zhang, J., Cullen, B. & Cullen, M. G. (1997). Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. EMBO Journal 16, 4606-4616.
Arthos, J., Rubbert, A., Rabin, R. L., Cicala, C., Machado, E., Wildt, K., Hanbach, M., Steenbeke, T. D., Swofford, R., Farber, J. M. & Fauci, A. S. (2000). CCR5 signal transduction in macrophages by human immunodeficiency virus and simian immunodeficiency virus envelopes. Journal of Virology 74, 6418-6424.
Asjo, B., Morfeldt Manson, L., Albert, J., Biberfeld, G., Karlsson, A., Lidman, K. & Fenyo, E. M. (1986). Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 2, 660-662.[Medline]
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., Meguro, K. & Fujino, M. (1999). A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proceedings of the National Academy of Sciences, USA 96, 5698-5703.
Baier, M. & Kurth, R. (1997). Fighting HIV-1 with IL-16. Nature Medicine 3, 605-606.[Medline]
Bakri, Y., Schiffer, C., Zennou, V., Charneau, P., Kahn, E., Benjouad, A., Gluckman, J. C. & Canque, B. (2001). The maturation of dendritic cells results in postintegration inhibition of HIV-1 replication. Journal of Immunology 166, 3780-3788.
Balotta, C., Bagnarelli, P., Corvasce, S., Mazzucchelli, R., Colombo, M. C., Papagno, L., Santambrogio, S., Ridolfo, A. L., Violin, M., Berlusconi, A., Velleca, R., Facchi, G., Moroni, M., Clementi, M. & Galli, M. (1999). Identification of two distinct subsets of long-term nonprogressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis. Journal of Infectious Diseases 180, 285-289.[Medline]
Bannert, N., Schenten, D., Craig, S. & Sodroski, J. (2000). The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. Journal of Virology 74, 10984-10993.
Baribaud, F., Edwards, T. G., Sharron, M., Brelot, A., Heveker, N., Price, K., Mortari, F., Alizon, M., Tsang, M. & Doms, R. W. (2001). Antigenically distinct conformations of CXCR4. Journal of Virology 75, 8957-8967.
Benkirane, M., Jin, D. Y., Chun, R. F., Koup, R. A. & Jeang, K. T. (1997). Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr532. Journal of Biological Chemistry 272, 30603-30606.
Berger, E. A., Doms, R. W., Fenyo, E.-M., Korber, B. T. M., Littman, D. R., Moore, J. P., Sattentau, Q. J., Schuitemaker, H., Sodroski, J. & Weiss, R. A. (1998). A new classification for HIV-1. Nature 391, 240.[Medline]
Blaak, H., van't Wout, A. B., Brouwer, M., Hooibrink, B., Hovenkamp, E. & Schuitemaker, H. (2000). In vivo HIV-1 infection of CD45RA+CD4+ T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4+ T cell decline. Proceedings of the National Academy of Sciences, USA 97, 1269-1274.
Bleul, C. C., Wu, L., Hoxie, J. A., Springer, T. A. & Mackay, C. R. (1997). The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proceedings of the National Academy of Sciences, USA 94, 1925-1930.
Brelot, A., Heveker, N., Adema, K., Hosie, M. J., Willett, B. & Alizon, M. (1999). Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. Journal of Virology 73, 2576-2586.
Briant, L., Coudronniere, N., Robert-Hebmann, V., Benkirane, M. & Devaux, C. (1996). Binding of HIV-1 virions or gp120-anti-gp120 immune complexes to HIV-1-infected quiescent peripheral blood mononuclear cells reveals latent infection. Journal of Immunology 156, 3994-4004.[Abstract]
Bron, R., Klasse, P. J., Wilkinson, D., Clapham, P. R., Pelchen Matthews, A., Power, C., Wells, T. N., Kim, J., Peiper, S. C., Hoxie, J. A. & Marsh, M. (1997). Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein. Journal of Virology 71, 8405-8415.[Abstract]
Cao, J., Sullivan, N., Desjardin, E., Parolin, C., Robinson, J., Wyatt, R. & Sodroski, J. (1997). Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. Journal of Virology 71, 9808-9012.[Abstract]
Carrington, M., Dean, M., Martin, M. P. & O'Brien, S. J. (1999). Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Human Molecular Genetics 8, 1939-1945.
Chackerian, B., Long, E. M., Luciw, P. A. & Overbaugh, J. (1997). Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. Journal of Virology 71, 3932-3939.[Abstract]
Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. (1997). Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273.[Medline]
Chan, D. C., Chutkowski, C. T. & Kim, P. S. (1998). Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proceedings of the National Academy of Sciences, USA 95, 15613-15617.
Chen, Z., Gettie, A., Ho, D. D. & Marx, P. A. (1998a). Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac. Virology 246, 113-124.[Medline]
Chen, Z., Kwon, D., Jin, Z., Monard, S., Telfer, P., Jones, M. S., Lu, C. Y., Aguilar, R. F., Ho, D. D. & Marx, P. A. (1998b). Natural infection of a homozygous 24 CCR5 red-capped mangabey with an R2b-tropic simian immunodeficiency virus. Journal of Experimental Medicine 188, 2057-2065.
Cho, M. W., Lee, M. K., Carney, M. C., Berson, J. F., Doms, R. W. & Martin, M. A. (1998). Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. Journal of Virology 72, 2509-2515.
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G., Newman, W., Gerard, N., Gerard, C. & Sodroski, J. (1996). The -chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135-1148.[Medline]
Choe, H., Farzan, M., Konkel, M., Martin, K., Sun, Y., Marcon, L., Cayabyab, M., Berman, M., Dorf, M. E., Gerard, N., Gerard, C. & Sodroski, J. (1998). The orphan seven-transmembrane receptor APJ supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. Journal of Virology 72, 6113-6118.
Cicala, C., Arthos, J., Ruiz, M., Vaccarezza, M., Rubbert, A., Riva, A., Wildt, K., Cohen, O. & Fauci, A. S. (1999). Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope. Journal of Immunology 163, 420-426.
Clapham, P. R. & Weiss, R. A. (1997). Immunodeficiency viruses. Spoilt for choice of co-receptors. Nature 388, 230-231.[Medline]
Clapham, P. R., Weber, J. N., Whitby, D., McIntosh, K., Dalgleish, A. G., Maddon, P. J., Deen, K. C., Sweet, R. W. & Weiss, R. A. (1989). Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 337, 368-370.[Medline]
Clapham, P. R., Blanc, D. & Weiss, R. A. (1991). Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus. Virology 181, 703-715.[Medline]
Clapham, P. R., McKnight, A., Talbot, S. & Wilkinson, D. (1996). HIV entry into cells by CD4-independent mechanisms. In HIV Infection in CD4- Cells , pp. 83-92. Edited by J. Fantini & J.-M. Sabatier. Leiden:ESCOM.
Cocchi, F., DeVico, A. L., Garzino Demo, A., Arya, S. K., Gallo, R. C. & Lusso, P. (1995). Identification of RANTES, MIP-1, and MIP-1
as the major HIV-suppressive factors produced by CD8+ T cells. Science 270, 1811-1815.[Abstract]
Cohen, O. J., Paolucci, S., Bende, S. M., Daucher, M., Moriuchi, H., Moriuchi, M., Cicala, C., Davey, R. T.Jr, Baird, B. & Fauci, A. S. (1998). CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-32. Journal of Virology 72, 6215-6217.
Corbeil, J. & Richman, D. D. (1995). Productive infection and subsequent interaction of CD4gp120 at the cellular membrane is required for HIV-induced apoptosis of CD4+ T cells. Journal of General Virology 76, 681-690.[Abstract]
Corbeil, J., Tremblay, M. & Richman, D. D. (1996). HIV-induced apoptosis requires the CD4 receptor cytoplasmic tail and is accelerated by interaction of CD4 with p56lck. Journal of Experimental Medicine 183, 39-48.[Abstract]
Cornelissen, M., Mulder-Kampinga, G., Veenstra, J., Zorgdrager, F., Kuiken, C., Hartman, S., Dekker, J., van der Hoek, L., Sol, C., Coutinho, R. & Goudsmit, J. (1995). Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. Journal of Virology 69, 1810-1818.[Abstract]
Cruikshank, W. W., Kornfeld, H. & Center, D. M. (1998). Signaling and functional properties of interleukin-16. International Reviews of Immunology 16, 523-540.[Medline]
Curtis, B. M., Scharnowske, S. & Watson, A. J. (1992). Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120. Proceedings of the National Academy of Sciences, USA 89, 8356-8360.[Abstract]
Daar, E. S., Li, X. L., Moudgil, T. & Ho, D. D. (1990). High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proceedings of the National Academy of Sciences, USA 87, 6574-6578.[Abstract]
Danieli, T., Pelletier, S. L., Henis, Y. I. & White, J. M. (1996). Membrane fusion mediated by the influenza virus hemagglutinin requires the concerted action of at least three hemagglutinin trimers. Journal of Cell Biology 133, 559-569.[Abstract]
Davis, C. B., Dikic, I., Unutmaz, D., Hill, C. M., Arthos, J., Siani, M. A., Thompson, D. A., Schlessinger, J. & Littman, D. R. (1997). Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. Journal of Experimental Medicine 186, 1793-1798.
Dean, M., Carrington, M., Winkler, C., Huttley, G. A., Smith, M. W., Allikmets, R., Goedert, J. J., Buchbinder, S. P., Vittinghoff, E., Gomperts, E., Donfield, S., Vlahov, D., Kaslow, R., Saah, A., Rinaldo, C., Detels, R. & O'Brien, S. J. (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273, 1856-1862.
Delezay, O., Koch, N., Yahi, N., Hammache, D., Tourres, C., Tamalet, C. & Fantini, J. (1997). Co-expression of CXCR4/fusin and galactosylceramide in the human intestinal epithelial cell line HT-29. AIDS 11, 1311-1318.[Medline]
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. B., Peiper, S. C., Schall, T. J., Littman, D. R. & Landau, N. R. (1996). Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666.[Medline]
Deng, H. K., Unutmaz, D., KewalRamani, V. N. & Littman, D. R. (1997). Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388, 296-300.[Medline]
Donzella, G. A., Schols, D., Lin, S. W., Este, J. A., Nagashima, K. A., Maddon, P. J., Allaway, G. P., Sakmar, T. P., Henson, G., De Clercq, E. & Moore, J. P. (1998). AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Medicine 4, 72-77.[Medline]
Doranz, B. J., Rucker, J., Yi, Y., Smyth, R. J., Samson, M., Peiper, S. C., Parmentier, M., Collman, R. G. & Doms, R. W. (1996). A dual-tropic primary HIV-1 isolate that uses fusin and the -chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85, 1149-1158.[Medline]
Doranz, B. J., Orsini, M. J., Turner, J. D., Hoffman, T. L., Berson, J. F., Hoxie, J. A., Peiper, S. C., Brass, L. F. & Doms, R. W. (1999). Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. Journal of Virology 73, 2752-2761.
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P. & Paxton, W. A. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667-673.[Medline]
Dutch, R. E., Jardetzky, T. S. & Lamb, R. A. (2000). Virus membrane fusion proteins: biological machines that undergo a metamorphosis. Bioscience Reports 20, 597-612.[Medline]
Earl, P. L., Doms, R. W. & Moss, B. (1990). Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proceedings of the National Academy of Sciences, USA 87, 648-652.[Abstract]
Edinger, A. L., Amedee, A., Miller, K., Doranz, B. J., Endres, M., Sharron, M., Samson, M., Lu, Z. H., Clements, J. E., Murphey Corb, M., Peiper, S. C., Parmentier, M., Broder, C. C. & Doms, R. W. (1997). Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proceedings of the National Academy of Sciences, USA 94, 4005-4010.
Edinger, A. L., Hoffman, T. L., Sharron, M., Lee, B., Yi, Y., Choe, W., Kolson, D. L., Mitrovic, B., Zhou, Y., Faulds, D., Collman, R. G., Hesselgesser, J., Horuk, R. & Doms, R. W. (1998). An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. Journal of Virology 72, 7934-7940.
Fantini, J., Cook, D. G., Nathanson, N., Spitalnik, S. L. & Gonzalez Scarano, F. (1993). Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proceedings of the National Academy of Sciences, USA 90, 2700-2704.[Abstract]
Farzan, M., Choe, H., Martin, K., Marcon, L., Hofmann, W., Karlsson, G., Sun, Y., Barrett, P., Marchand, N., Sullivan, N., Gerard, N., Gerard, C. & Sodroski, J. (1997). Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. Journal of Experimental Medicine 186, 405-411.
Farzan, M., Choe, H., Vaca, L., Martin, K., Sun, Y., Desjardins, E., Ruffing, N., Wu, L., Wyatt, R., Gerard, N., Gerard, C. & Sodroski, J. (1998). A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. Journal of Virology 72, 1160-1164.
Feng, Y., Broder, C. C., Kennedy, P. E. & Berger, E. A. (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877.[Abstract]
Fortin, J. F., Barbeau, B., Hedman, H., Lundgren, E. & Tremblay, M. J. (1999). Role of the leukocyte function antigen-1 conformational state in the process of human immunodeficiency virus type 1-mediated syncytium formation and virus infection. Virology 257, 228-238.[Medline]
Gabuzda, D. & Wang, J. (2000). Chemokine receptors and mechanisms of cell death in HIV neuropathogenesis. Journal of Neurovirology 6 (Suppl. 1), S24S32.
Gartner, S., Markovits, P., Markovitz, D. M., Kaplan, M. H., Gallo, R. C. & Popovic, M. (1986). The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233, 215-219.[Medline]
Geijtenbeek, T. B., Kwon, D. S., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C., Middel, J., Cornelissen, I. L., Nottet, H. S., KewalRamani, V. N., Littman, D. R., Figdor, C. G. & van Kooyk, Y. (2000). DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587-597.[Medline]
Ghorpade, A., Nukuna, A., Che, M., Haggerty, S., Persidsky, Y., Carter, E., Carhart, L., Shafer, L. & Gendelman, H. E. (1998). Human immunodeficiency virus neurotropism: an analysis of viral replication and cytopathicity for divergent strains in monocytes and microglia. Journal of Virology 72, 3340-3350.
Gonzalez, E., Dhanda, R., Bamshad, M., Mummidi, S., Geevarghese, R., Catano, G., Anderson, S. A., Walter, E. A., Stephan, K. T., Hammer, M. F., Mangano, A., Sen, L., Clark, R. A., Ahuja, S. S., Dolan, M. J. & Ahuja, S. K. (2001). Global survey of genetic variation in CCR5, RANTES, and MIP-1: impact on the epidemiology of the HIV-1 pandemic. Proceedings of the National Academy of Sciences, USA 98, 5199-5204.
Gorry, P. R., Bristol, G., Zack, J. A., Ritola, K., Swanstrom, R., Birch, C. J., Bell, J. E., Bannert, N., Crawford, K., Wang, H., Schols, D., De Clercq, E., Kunstman, K., Wolinsky, S. M. & Gabuzda, D. (2001). Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. Journal of Virology 75, 10073-10089.
Gosling, J., Monteclaro, F. S., Atchison, R. E., Arai, H., Tsou, C. L., Goldsmith, M. A. & Charo, I. F. (1997). Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proceedings of the National Academy of Sciences, USA 94, 5061-5066.
Granelli-Piperno, A., Delgado, E., Finkel, V., Paxton, W. & Steinman, R. M. (1998). Immature dendritic cells selectively replicate macrophagetropic (M- tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. Journal of Virology 72, 2733-2737.
Guillon, C., van der Ende, M. E., Boers, P. H., Gruters, R. A., Schutten, M. & Osterhaus, A. D. (1998). Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. Journal of Virology 72, 6260-6263.
Hallenberger, S., Moulard, M., Sordel, M., Klenk, H. D. & Garten, W. (1997). The role of eukaryotic subtilisin-like endoproteases for the activation of human immunodeficiency virus glycoproteins in natural host cells. Journal of Virology 71, 1036-1045.[Abstract]
Harouse, J. M., Bhat, S., Spitalnik, S. L., Laughlin, M., Stefano, K., Silberberg, D. H. & Gonzalez Scarano, F. (1991). Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science 253, 320-323.[Medline]
Harouse, J. M., Gettie, A., Tan, R. C., Blanchard, J. & Cheng-Mayer, C. (1999). Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284, 816-819.
Harrop, H. A., Coombe, D. R. & Rider, C. C. (1994). Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS 8, 183-192.[Medline]
He, J., Chen, Y., Farzan, M., Choe, H., Ohagen, A., Gartner, S., Busciglio, J., Yang, X., Hofmann, W., Newman, W., Mackay, C. R., Sodroski, J. & Gabuzda, D. (1997). CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385, 645-649.[Medline]
Healey, D., Dianda, L., Moore, J. P., McDougal, J. S., Moore, M. J., Estess, P., Buck, D., Kwong, P. D., Beverley, P. C. & Sattentau, Q. J. (1990). Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. Journal of Experimental Medicine 172, 1233-1242.[Abstract]
Hesselgesser, J., Halks-Miller, M., DelVecchio, V., Peiper, S. C., Hoxie, J., Kolson, D. L., Taub, D. & Horuk, R. (1997). CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. Current Biology 7, 112-121.[Medline]
Hibbitts, S., Reeves, J. D., Simmons, G., Gray, P. W., Epstein, L. G., Schols, D., De Clercq, E., Wells, T. N. C., Proudfoot, A. E. I. & Clapham, P. R. (1999). Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1. AIDS Research and Human Retroviruses 15, 989-1000.[Medline]
Hill, C. M., Kwon, D., Jones, M., Davis, C. B., Marmon, S., Daugherty, B. L., DeMartino, J. A., Springer, M. S., Unutmaz, D. & Littman, D. R. (1998). The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology 248, 357-371.[Medline]
Hoffman, T. L., LaBranche, C. C., Zhang, W., Canziani, G., Robinson, J., Chaiken, I., Hoxie, J. A. & Doms, R. W. (1999). Stable exposure of the coreceptor-binding site in a CD4-independent HIV- 1 envelope protein. Proceedings of the National Academy of Sciences, USA 96, 6359-6364.
Howard, O. M., Shirakawa, A. K., Turpin, J. A., Maynard, A., Tobin, G. J., Carrington, M., Oppenheim, J. J. & Dean, M. (1999). Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 co-receptor and ligand binding function. Journal of Biological Chemistry 274, 16228-16234.
Huang, Y., Paxton, W. A., Wolinsky, S. M., Neumann, A. U., Zhang, L., He, T., Kang, S., Ceradini, D., Jin, Z., Yazdanbakhsh, K., Kunstman, K., Erickson, D., Dragon, E., Landau, N. R., Phair, J., Ho, D. D. & Koup, R. A. (1996). The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Medicine 2, 1240-1243.[Medline]
Huang, B., Yachou, A., Fleury, S., Hendrickson, W. A. & Sekaly, R. P. (1997). Analysis of the contact sites on the CD4 molecule with class II MHC molecule: co-ligand versus co-receptor function. Journal of Immunology 158, 216-225.[Abstract]
Hwang, S. S., Boyle, T. J., Lyerly, H. K. & Cullen, B. R. (1991). Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253, 71-74.[Medline]
Ito, M., Baba, M., Sato, A., Pauwels, R., De Clercq, E. & Shigeta, S. (1987). Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Research 7, 361-367.[Medline]
Janeway, C. A.Jr (1992). The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annual Review of Immunology 10, 645-674.[Medline]
Kaneko, Y., Yoshida, O., Nakagawa, R., Yoshida, T., Date, M., Ogihara, S., Shioya, S., Matsuzawa, Y., Nagashima, N., Irie, Y. and others (1990). Inhibition of HIV-1 infectivity with curdlan sulfate in vitro. Biochemical Pharmacology 39, 793797.
Kelloway, J. S. (1997). Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma. Annals of Pharmacotherapy 31, 1012-1021.[Abstract]
Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., Matthews, T., Johnson, M. R., Nowak, M. A., Shaw, G. M. & Saag, M. S. (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Medicine 4, 1302-1307.[Medline]
Kledal, T. N., Rosenkilde, M. M., Coulin, F., Simmons, G., Johnsen, A. H., Alouani, S., Power, C. A., Luttichau, H. R., Gerstoft, J., Clapham, P. R., Clark Lewis, I., Wells, T. N. C. & Schwartz, T. W. (1997). A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 277, 1656-1659.
Koito, A., Harrowe, G., Levy, J. A. & Cheng-Mayer, C. (1994). Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. Journal of Virology 68, 2253-2259.[Abstract]
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J. & Hendrickson, W. A. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659.[Medline]
Lambotte, O., Taoufik, Y., de Goer, M. G., Wallon, C., Goujard, C. & Delfraissy, J. F. (2000). Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 23, 114-119.[Medline]
Lapham, C. K., Zaitseva, M. B., Lee, S., Romanstseva, T. & Golding, H. (1999). Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5. Nature Medicine 5, 303-308.[Medline]
Larkin, M., Childs, R. A., Matthews, T. J., Thiel, S., Mizuochi, T., Lawson, A. M., Savill, J. S., Haslett, C., Diaz, R. & Feizi, T. (1989). Oligosaccharide-mediated interactions of the envelope glycoprotein gp120 of HIV-1 that are independent of CD4 recognition. AIDS 3, 793-798.[Medline]
Lathey, J. L., Pratt, R. D. & Spector, S. A. (1997). Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1. Journal of Infectious Diseases 175, 231-232.[Medline]
Lee, B., Doranz, B. J., Rana, S., Yi, Y., Mellado, M., Frade, J. M., Martinez, A. C., O'Brien, S. J., Dean, M., Collman, R. G. & Doms, R. W. (1998). Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. Journal of Virology 72, 7450-7458.
Lee, B., Sharron, M., Blanpain, C., Doranz, B. J., Vakili, J., Setoh, P., Berg, E., Liu, G., Guy, H. R., Durell, S. R., Parmentier, M., Chang, C. N., Price, K., Tsang, M. & Doms, R. W. (1999). Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. Journal of Biological Chemistry 274, 9617-9626.
Lee, S., Tiffany, H. L., King, L., Murphy, P. M., Golding, H. & Zaitseva, M. B. (2000). CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor. Journal of Virology 74, 6946-6952.
Liu, H., Chao, D., Nakayama, E. E., Taguchi, H., Goto, M., Xin, X., Takamatsu, J., Saito, H., Ishikawa, Y., Akaza, T., Juji, T., Takebe, Y., Ohishi, T., Fukutake, K., Maruyama, Y., Yashiki, S., Sonoda, S., Nakamura, T., Nagai, Y., Iwamoto, A. & Shioda, T. (1999a). Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proceedings of the National Academy of Sciences, USA 96, 4581-4585.
Liu, Y., Cruikshank, W. W., O'Loughlin, T., O'Reilly, P., Center, D. M. & Kornfeld, H. (1999b). Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation. Journal of Biological Chemistry 274, 23387-23395.
Lu, Z., Berson, J. F., Chen, Y., Turner, J. D., Zhang, T., Sharron, M., Jenks, M. H., Wang, Z., Kim, J., Rucker, J., Hoxie, J. A., Peiper, S. C. & Doms, R. W. (1997). Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proceedings of the National Academy of Sciences, USA 94, 6426-6431.
Lusso, P., Secchiero, P., Crowley, R. W., Garzino-Demo, A., Berneman, Z. N. & Gallo, R. C. (1994). CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 91, 3872-3876.[Abstract]
Ma, Q., Jones, D., Borghesani, P. R., Segal, R. A., Nagasawa, T., Kishimoto, T., Bronson, R. T. & Springer, T. A. (1998). Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proceedings of the National Academy of Sciences, USA 95, 9448-9453.
McClure, M. O., Moore, J. P., Blanc, D. F., Scotting, P., Cook, G. M., Keynes, R. J., Weber, J. N., Davies, D. & Weiss, R. A. (1992). Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. AIDS Research and Human Retroviruses 8, 19-26.[Medline]
McDermott, D. H., Zimmerman, P. A., Guignard, F., Kleeberger, C. A., Leitman, S. F. & Murphy, P. M. (1998). CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 352, 866-870.[Medline]
McDermott, D. H., Beecroft, M. J., Kleeberger, C. A., Al-Sharif, F. M., Ollier, W. E., Zimmerman, P. A., Boatin, B. A., Leitman, S. F., Detels, R., Hajeer, A. H. & Murphy, P. M. (2000). Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 14, 2671-2678.[Medline]
Mack, M., Luckow, B., Nelson, P. J., Cihak, J., Simmons, G., Clapham, P. R., Signoret, N., Marsh, M., Stangassinger, M., Borlat, F., Wells, T. N., Schlondorff, D. & Proudfoot, A. E. (1998). Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. Journal of Experimental Medicine 187, 1215-1224.
McKnight, A., Dittmar, M. T., Moniz Periera, J., Ariyoshi, K., Reeves, J. D., Hibbitts, S., Whitby, D., Aarons, E., Proudfoot, A. E., Whittle, H. & Clapham, P. R. (1998). A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. Journal of Virology 72, 4065-4071.
Maddon, P. J., Dalgleish, A. G., McDougal, J. S., Clapham, P. R., Weiss, R. A. & Axel, R. (1986). The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47, 333-348.[Medline]
Mangano, A., Kopka, J., Batalla, M., Bologna, R. & Sen, L. (2000). Protective effect of CCR264I and not of CCR5-32 and SDF13'A in pediatric HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 23, 52-57.[Medline]
Martin, M. P., Carrington, M., Dean, M., O'Brien, S. J., Sheppard, H. W., Wegner, S. A. & Michael, N. L. (1998a). CXCR4 polymorphisms and HIV-1 pathogenesis. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 19, 430.
Martin, M. P., Dean, M., Smith, M. W., Winkler, C., Gerrard, B., Michael, N. L., Lee, B., Doms, R. W., Margolick, J., Buchbinder, S., Goedert, J. J., O'Brien, T. R., Hilgartner, M. W., Vlahov, D., O'Brien, S. J. & Carrington, M. (1998b). Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282, 1907-1911.
Masurier, C., Salomon, B., Guettari, N., Pioche, C., Lachapelle, F., Guigon, M. & Klatzmann, D. (1998). Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice. Journal of Virology 72, 7822-7829.
Meister, S., Otto, C., Papkalla, A., Krumbiegel, M., Pohlmann, S. & Kirchhoff, F. (2001). Basic amino acid residues in the V3 loop of simian immunodeficiency virus envelope alter viral coreceptor tropism and infectivity but do not allow efficient utilization of CXCR4 as entry cofactor. Virology 284, 287-296.[Medline]
Mellado, M., Rodriguez-Frade, J. M., Vila-Coro, A. J., de Ana, A. M. & Martinez, A. C. (1999). Chemokine control of HIV-1 infection. Nature 400, 723-724.[Medline]
Michael, N. L. & Moore, J. P. (1999). HIV-1 entry inhibitors: evading the issue. Nature Medicine 5, 740-742.[Medline]
Michael, N. L., Nelson, J. A., KewalRamani, V. N., Chang, G., O'Brien, S. J., Mascola, J. R., Volsky, B., Louder, M., White, G. C.II, Littman, D. R., Swanstrom, R. & O'Brien, T. R. (1998). Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 32. Journal of Virology 72, 6040-6047.
Mitsuya, H., Looney, D. J., Kuno, S., Ueno, R., Wong-Staal, F. & Broder, S. (1988). Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 240, 646-649.[Medline]
Moebius, U., Pallai, P., Harrison, S. C. & Reinherz, E. L. (1993). Delineation of an extended surface contact area on human CD4 involved in class II major histocompatibility complex binding. Proceedings of the National Academy of Sciences, USA 90, 8259-8263.
Moir, S., Perreault, J. & Poulin, L. (1996). Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4. Journal of Virology 70, 8019-8028.[Abstract]
Mondor, I., Ugolini, S. & Sattentau, Q. J. (1998). Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. Journal of Virology 72, 3623-3634.
Moore, J. P., McKeating, J. A., Weiss, R. A. & Sattentau, Q. J. (1990). Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250, 1139-1142.[Medline]
Moore, J. P., McKeating, J. A., Huang, Y. X., Ashkenazi, A. & Ho, D. D. (1992). Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. Journal of Virology 66, 235-243.[Abstract]
Morner, A., Bjorndal, A., Albert, J., Kewalramani, V. N., Littman, D. R., Inoue, R., Thorstensson, R., Fenyo, E. M. & Bjorling, E. (1999). Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. Journal of Virology 73, 2343-2349.
Moulard, M., Lortat-Jacob, H., Mondor, I., Roca, G., Wyatt, R., Sodroski, J., Zhao, L., Olson, W., Kwong, P. D. & Sattentau, Q. J. (2000). Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. Journal of Virology 74, 1948-1960.
Mummidi, S., Ahuja, S. S., Gonzalez, E., Anderson, S. A., Santiago, E. N., Stephan, K. T., Craig, F. E., O'Connell, P., Tryon, V., Clark, R. A., Dolan, M. J. & Ahuja, S. K. (1998). Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nature Medicine 4, 786-793.[Medline]
Myszka, D. G., Sweet, R. W., Hensley, P., Brigham-Burke, M., Kwong, P. D., Hendrickson, W. A., Wyatt, R., Sodroski, J. & Doyle, M. L. (2000). Energetics of the HIV gp120CD4 binding reaction. Proceedings of the National Academy of Sciences, USA 97, 9026-9031.
Nakayama, E. E., Hoshino, Y., Xin, X., Liu, H., Goto, M., Watanabe, N., Taguchi, H., Hitani, A., Kawana-Tachikawa, A., Fukushima, M., Yamada, K., Sugiura, W., Oka, S. I., Ajisawa, A., Sato, H., Takebe, Y., Nakamura, T., Nagai, Y., Iwamoto, A. & Shioda, T. (2000). Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. Journal of Virology 74, 5452-5459.
Olson, W. C., Rabut, G. E., Nagashima, K. A., Tran, D. N., Anselma, D. J., Monard, S. P., Segal, J. P., Thompson, D. A., Kajumo, F., Guo, Y., Moore, J. P., Maddon, P. J. & Dragic, T. (1999). Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. Journal of Virology 73, 4145-4155.
Ostrowski, M. A., Chun, T. W., Justement, S. J., Motola, I., Spinelli, M. A., Adelsberger, J., Ehler, L. A., Mizell, S. B., Hallahan, C. W. & Fauci, A. S. (1999). Both memory and CD45RA+/CD62L+ naive CD4+ T cells are infected in human immunodeficiency virus type 1-infected individuals. Journal of Virology 73, 6430-6435.
Owen, S. M., Masciotra, S., Novembre, F., Yee, J., Switzer, W. M., Ostyula, M. & Lal, R. B. (2000). Simian immunodeficiency viruses of diverse origin can use CXCR4 as a coreceptor for entry into human cells. Journal of Virology 74, 5702-5708.
Owman, C., Garzino-Demo, A., Cocchi, F., Popovic, M., Sabirsh, A. & Gallo, R. C. (1998). The leukotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. Proceedings of the National Academy of Sciences, USA 95, 9530-9534.
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M. & Miyano, M. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739-745.
Paquette, J. S., Fortin, J. F., Blanchard, L. & Tremblay, M. J. (1998). Level of ICAM-1 surface expression on virus producer cells influences both the amount of virion-bound host ICAM-1 and human immunodeficiency virus type 1 infectivity. Journal of Virology 72, 9329-9336.
Patterson, S., Robinson, S. P., English, N. R. & Knight, S. C. (1999). Subpopulations of peripheral blood dendritic cells show differential susceptibility to infection with a lymphotropic strain of HIV-1. Immunology Letters 66, 111-116.[Medline]
Patterson, S., Rae, A., Hockey, N., Gilmour, J. & Gotch, F. (2001). Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus. Journal of Virology 75, 6710-6713.
Philpott, S., Burger, H., Charbonneau, T., Grimson, R., Vermund, S. H., Visosky, A., Nachman, S., Kovacs, A., Tropper, P., Frey, H. & Weiser, B. (1999). CCR5 genotype and resistance to vertical transmission of HIV-1. Journal of Acquired Immune Deficiency Syndromes 21, 189-193.[Medline]
Picard, L., Simmons, G., Power, C. A., Meyer, A., Weiss, R. A. & Clapham, P. R. (1997a). Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. Journal of Virology 71, 5003-5011.[Abstract]
Picard, L., Wilkinson, D. A., McKnight, A., Gray, P. W., Hoxie, J. A., Clapham, P. R. & Weiss, R. A. (1997b). Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry. Virology 231, 105-111.[Medline]
Platt, E. J., Kuhmann, S. E., Rose, P. P. & Kabat, D. (2001). Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region. Journal of Virology 75, 12266-12278.
Pohlmann, S., Soilleux, E. J., Baribaud, F., Leslie, G. J., Morris, L. S., Trowsdale, J., Lee, B., Coleman, N. & Doms, R. W. (2001). DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proceedings of the National Academy of Sciences, USA 98, 2670-2675.
Power, C., McArthur, J. C., Johnson, R. T., Griffin, D. E., Glass, J. D., Perryman, S. & Chesebro, B. (1994). Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. Journal of Virology 68, 4643-4649.[Abstract]
Puffer, B. A., Pohlmann, S., Edinger, A. L., Carlin, D., Sanchez, M. D., Reitter, J., Watry, D. D., Fox, H. S., Desrosiers, R. C. & Doms, R. W. (2002). CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. Journal of Virology 76, 2595-2605.
Quillent, C., Oberlin, E., Braun, J., Rousset, D., Gonzalez-Canali, G., Metais, P., Montagnier, L., Virelizier, J. L., Arenzana-Seisdedos, F. & Beretta, A. (1998). HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 351, 14-18.[Medline]
Ravichandran, K. S., Collins, T. L. & Burakoff, S. J. (1996). CD4 and signal transduction. Current Topics in Microbiology and Immunology 205, 47-62.[Medline]
Reece, J. C., Handley, A. J., Anstee, E. J., Morrison, W. A., Crowe, S. M. & Cameron, P. U. (1998). HIV-1 selection by epidermal dendritic cells during transmission across human skin. Journal of Experimental Medicine 187, 1623-1631.
Reeves, J. D., McKnight, A., Potempa, S., Simmons, G., Gray, P. W., Power, C. A., Wells, T., Weiss, R. A. & Talbot, S. J. (1997). CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology 231, 130-134.[Medline]
Reeves, J. D., Hibbitts, S., Simmons, G., McKnight, A., Azevedo-Pereira, J. M., Moniz-Pereira, J. & Clapham, P. R. (1999). Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. Journal of Virology 73, 7795-7804.
Rojo, D., Suetomi, K. & Navarro, J. (1999). Structural biology of chemokine receptors. Biological Research 32, 263-272.[Medline]
Ross, T. M. & Cullen, B. R. (1998). The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. Proceedings of the National Academy of Sciences, USA 95, 7682-7686.
Rucker, J., Edinger, A. L., Sharron, M., Samson, M., Lee, B., Berson, J. F., Yi, Y., Margulies, B., Collman, R. G., Doranz, B. J., Parmentier, M. & Doms, R. W. (1997). Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. Journal of Virology 71, 8999-9007.[Abstract]
Saha, K., Bentsman, G., Chess, L. & Volsky, D. J. (1998). Endogenous production of -chemokines by CD4+, but not CD8+, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. Journal of Virology 72, 876-881.
Saito, Y., Sharer, L. R., Epstein, L. G., Michaels, J., Mintz, M., Louder, M., Golding, K., Cvetkovich, T. A. & Blumberg, B. M. (1994). Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology 44, 474-481.[Abstract]
Salzwedel, K. & Berger, E. A. (2000). Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41. Proceedings of the National Academy of Sciences, USA 97, 12794-12799.
Samson, M., Edinger, A. L., Stordeur, P., Rucker, J., Verhasselt, V., Sharron, M., Govaerts, C., Mollereau, C., Vassart, G., Doms, R. W. & Parmentier, M. (1998). ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. European Journal of Immunology 28, 1689-1700.[Medline]
Sattentau, Q. J., Clapham, P. R., Weiss, R. A., Beverley, P. C., Montagnier, L., Alhalabi, M. F., Gluckmann, J. C. & Klatzmann, D. (1988). The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule. AIDS 2, 101-105.[Medline]
Scala, E., D'Offizi, G., Rosso, R., Turriziani, O., Ferrara, R., Mazzone, A. M., Antonelli, G., Aiuti, F. & Paganelli, R. (1997). C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. Journal of Immunology 158, 4485-4492.[Abstract]
Scarlatti, G., Tresoldi, E., Bjorndal, A., Fredriksson, R., Colognesi, C., Deng, H. K., Malnati, M. S., Plebani, A., Siccardi, A. G., Littman, D. R., Fenyo, E. M. & Lusso, P. (1997). In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature Medicine 3, 1259-1265.[Medline]
Schnittman, S. M., Psallidopoulos, M. C., Lane, H. C., Thompson, L., Baseler, M., Massari, F., Fox, C. H., Salzman, N. P. & Fauci, A. S. (1989). The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 245, 305-308.[Medline]
Schols, D. & De Clercq, E. (1998). The simian immunodeficiency virus mnd(GB-1) strain uses CXCR4, not CCR5, as coreceptor for entry in human cells. Journal of General Virology 79, 2203-2205.[Abstract]
Schooley, R. T., Merigan, T. C., Gaut, P., Hirsch, M. S., Holodniy, M., Flynn, T., Liu, S., Byington, R. E., Henochowicz, S., Gubish, E. and others (1990). Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase III escalating dosage trial. Annals of Internal Medicine 112, 247253.[Medline]
Seddiki, N., Ramdani, A., Saffar, L., Portoukalian, J., Gluckman, J. C. & Gattegno, L. (1994). A monoclonal antibody directed to sulfatide inhibits the binding of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein to macrophages but not their infection by the virus. Biochimica et Biophysica Acta 1225, 289-296.[Medline]
Shankarappa, R., Margolick, J. B., Gange, S. J., Rodrigo, A. G., Upchurch, D., Farzadegan, H., Gupta, P., Rinaldo, C. R., Learn, G. H., He, X., Huang, X. L. & Mullins, J. I. (1999). Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. Journal of Virology 73, 10489-10502.
Sharron, M., Pohlmann, S., Price, K., Lolis, E., Tsang, M., Kirchhoff, F., Doms, R. W. & Lee, B. (2000). Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood 96, 41-49.
Shaunak, S., Thornton, M., John, S., Teo, I., Peers, E., Mason, P., Krausz, T. & Davies, D. S. (1998). Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDS. AIDS 12, 399-409.[Medline]
Shieh, J. T., Albright, A. V., Sharron, M., Gartner, S., Strizki, J., Doms, R. W. & Gonzalez Scarano, F. (1998). Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia. Journal of Virology 72, 4243-4249.
Shieh, J. T., Martin, J., Baltuch, G., Malim, M. H. & Gonzalez-Scarano, F. (2000). Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains. Journal of Virology 74, 693-701.
Shimizu, N., Soda, Y., Kanbe, K., Liu, H. Y., Mukai, R., Kitamura, T. & Hoshino, H. (2000). A putative G protein-coupled receptor, RDC1, is a novel coreceptor for human and simian immunodeficiency viruses. Journal of Virology 74, 619-626.
Simmons, G., Wilkinson, D., Reeves, J. D., Dittmar, M. T., Beddows, S., Weber, J., Carnegie, G., Desselberger, U., Gray, P. W., Weiss, R. A. & Clapham, P. R. (1996). Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. Journal of Virology 70, 8355-8360.[Abstract]
Simmons, G., Clapham, P. R., Picard, L., Offord, R. E., Rosenkilde, M. M., Schwartz, T. W., Buser, R., Wells, T. N. C. & Proudfoot, A. E. (1997). Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276, 276-279.
Simmons, G., Reeves, J. D., Hibbitts, S., Stine, J. T., Gray, P. W., Proudfoot, A. E. & Clapham, P. R. (2000). Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunological Reviews 177, 112-126.[Medline]
Skehel, J. J., Bizebard, T., Bullough, P. A., Hughson, F. M., Knossow, M., Steinhauer, D. A., Wharton, S. A. & Wiley, D. C. (1995). Membrane fusion by influenza hemagglutinin. Cold Spring Harbor Symposia on Quantitative Biology 60, 573-580.[Medline]
Smith, M. W., Dean, M., Carrington, M., Winkler, C., Huttley, G. A., Lomb, D. A., Goedert, J. J., O'Brien, T. R., Jacobson, L. P., Kaslow, R., Buchbinder, S., Vittinghoff, E., Vlahov, D., Hoots, K., Hilgartner, M. W. & OBrien, S. J. (1997). Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 277, 959-965.
Sol, N., Ferchal, F., Braun, J., Pleskoff, O., Treboute, C., Ansart, I. & Alizon, M. (1997). Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2. Journal of Virology 71, 8237-8244.[Abstract]
Sommerfelt, M. A. (1999). Retrovirus receptors. Journal of General Virology 80, 3049-3064.
Strizki, J. M., Xu, S., Wagner, N. E., Wojcik, L., Liu, J., Hou, Y., Endres, M., Palani, A., Shapiro, S., Clader, J. W., Greenlee, W. J., Tagat, J. R., McCombie, S., Cox, K., Fawzi, A. B., Chou, C. C., Pugliese-Sivo, C., Davies, L., Moreno, M. E., Ho, D. D., Trkola, A., Stoddart, C. A., Moore, J. P., Reyes, G. R. & Baroudy, B. M. (2001). SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proceedings of the National Academy of Sciences, USA 98, 12718-12723.
Tersmette, M., de Goede, R. E., Al, B. J., Winkel, I. N., Gruters, R. A., Cuypers, H. T., Huisman, H. G. & Miedema, F. (1988). Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Journal of Virology 62, 2026-2032.[Medline]
Trkola, A., Dragic, T., Arthos, J., Binley, J. M., Olson, W. C., Allaway, G. P., Cheng Mayer, C., Robinson, J., Maddon, P. J. & Moore, J. P. (1996). CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384, 184-187.[Medline]
Truong, M. J., Darcissac, E. C., Hermann, E., Dewulf, J., Capron, A. & Bahr, G. M. (1999). Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic cells. Journal of Virology 73, 7008-7013.
Tscherning, C., Alaeus, A., Fredriksson, R., Bjorndal, A., Deng, H., Littman, D. R., Fenyo, E. M. & Albert, J. (1998). Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 241, 181-188.[Medline]
Valentin, A., Albert, J., Fenyo, E. M. & Asjo, B. (1994). Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates. Journal of Virology 68, 6684-6689.[Abstract]
Valentin, A., Lu, W., Rosati, M., Schneider, R., Albert, J., Karlsson, A. & Pavlakis, G. N. (1998). Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. Proceedings of the National Academy of Sciences, USA 95, 8886-8891.
van Rij, R. P., Broersen, S., Goudsmit, J., Coutinho, R. A. & Schuitemaker, H. (1998). The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 12, F85-F90.[Medline]
Viglianti, G. A., Parada, N. A., Maciaszek, J. W., Kornfeld, H., Center, D. M. & Cruikshank, W. W. (1997). IL-16 anti-HIV-1 therapy. Nature Medicine 3, 938.[Medline]
Vignali, D. A., Carson, R. T., Chang, B., Mittler, R. S. & Strominger, J. L. (1996). The two membrane proximal domains of CD4 interact with the T cell receptor. Journal of Experimental Medicine 183, 2097-2107.[Abstract]
Vyakarnam, A., Eyeson, J., Teo, I., Zuckerman, M., Babaahmady, K., Schuitemaker, H., Shaunak, S., Rostron, T., Rowland-Jones, S., Simmons, G. & Clapham, P. (2001). Evidence for a post-entry barrier to R5 HIV-1 infection of CD4 memory T cells. AIDS 15, 1613-1626.[Medline]
Wang, Z. X., Berson, J. F., Zhang, T. Y., Cen, Y. H., Sun, Y., Sharron, M., Lu, Z. H. & Peiper, S. C. (1998). CXCR4 sequences involved in coreceptor determination of human immunodeficiency virus type-1 tropism. Unmasking of activity with M-tropic Env glycoproteins. Journal of Biological Chemistry 273, 15007-15015.
Weiss, R. A., Clapham, P., Nagy, K. & Hoshino, H. (1985). Envelope properties of human T-cell leukemia viruses. Current Topics in Microbiology and Immunology 115, 235-246.[Medline]
Weiss, C. D., Levy, J. A. & White, J. M. (1990). Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. Journal of Virology 64, 5674-5677.[Medline]
Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J. & Wiley, D. C. (1997). Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430.[Medline]
Weissman, D., Rabin, R. L., Arthos, J., Rubbert, A., Dybul, M., Swofford, R., Venkatesan, S., Farber, J. M. & Fauci, A. S. (1997). Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389, 981-985.[Medline]
Westervelt, P., Gendelman, H. E. & Ratner, L. (1991). Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proceedings of the National Academy of Sciences, USA 88, 3097-3101.[Abstract]
Wilkinson, D. A., Operskalski, E. A., Busch, M. P., Mosley, J. W. & Koup, R. A. (1998). A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. Journal of Infectious Diseases 178, 1163-1166.[Medline]
Winkler, C., Modi, W., Smith, M. W., Nelson, G. W., Wu, X., Carrington, M., Dean, M., Honjo, T., Tashiro, K., Yabe, D., Buchbinder, S., Vittinghoff, E., Goedert, J. J., O'Brien, T. R., Jacobson, L. P., Detels, R., Donfield, S., Willoughby, A., Gomperts, E., Vlahov, D., Phair, J. & O'Brien, S. J. (1998). Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 279, 389-393.
Wu, L., Gerard, N. P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., Borsetti, A., Cardoso, A. A., Desjardin, E., Newman, W., Gerard, C. & Sodroski, J. (1996). CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384, 179-183.[Medline]
Wu, L., LaRosa, G., Kassam, N., Gordon, C. J., Heath, H., Ruffing, N., Chen, H., Humblias, J., Samson, M., Parmentier, M., Moore, J. P. & Mackay, C. R. (1997a). Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. Journal of Experimental Medicine 186, 1373-1381.
Wu, L., Paxton, W. A., Kassam, N., Ruffing, N., Rottman, J. B., Sullivan, N., Choe, H., Sodroski, J., Newman, W., Koup, R. A. & Mackay, C. R. (1997b). CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. Journal of Experimental Medicine 185, 1681-1691.
Xiao, X., Wu, L., Stantchev, T. S., Feng, Y. R., Ugolini, S., Chen, H., Shen, Z., Riley, J. L., Broder, C. C., Sattentau, Q. J. & Dimitrov, D. S. (1999). Constitutive cell surface association between CD4 and CCR5. Proceedings of the National Academy of Sciences, USA 96, 7496-7501.
Yachou, A. & Sekaly, R. P. (1999). Binding of soluble recombinant HIV envelope glycoprotein, rgp120, induces conformational changes in the cellular membrane-anchored CD4 molecule. Biochemical and Biophysical Research Communications 265, 428-433.[Medline]
Yasukawa, M., Inoue, Y., Ohminami, H., Sada, E., Miyake, K., Tohyama, T., Shimada, T. & Fujita, S. (1997). Human herpesvirus 7 infection of lymphoid and myeloid cell lines transduced with an adenovirus vector containing the CD4 gene. Journal of Virology 71, 1708-1712.[Abstract]
Yasukawa, M., Hasegawa, A., Sakai, I., Ohminami, H., Arai, J., Kaneko, S., Yakushijin, Y., Maeyama, K., Nakashima, H., Arakaki, R. & Fujita, S. (1999). Down-regulation of CXCR4 by human herpesvirus 6 (HHV-6) and HHV-7. Journal of Immunology 162, 5417-5422.
Zaitseva, M., Blauvelt, A., Lee, S., Lapham, C. K., Klaus-Kovtun, V., Mostowski, H., Manischewitz, J. & Golding, H. (1997). Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nature Medicine 3, 1369-1375.[Medline]
Zhang, Y. J. & Moore, J. P. (1999). Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? Journal of Virology 73, 3443-3448.
Zhang, Y., Lou, B., Lal, R. B., Gettie, A., Marx, P. A. & Moore, J. P. (2000). The use of inhibitors to evaluate co-receptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. Journal of Virology 74, 6893-6910.
Zhou, P., Goldstein, S., Devadas, K., Tewari, D. & Notkins, A. L. (1997). Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nature Medicine 3, 659-664.[Medline]
Zhou, G., Ferrer, M., Chopra, R., Kapoor, T. M., Strassmaier, T., Weissenhorn, W., Skehel, J. J., Oprian, D., Schreiber, S. L., Harrison, S. C. & Wiley, D. C. (2000). The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorganic and Medicinal Chemistry Letters 8, 2219-2227.
Zink, M. C., Spelman, J. P., Robinson, R. B. & Clements, J. E. (1998). SIV infection of macaques: modeling the progression to AIDS dementia. Journal of Neurovirology 4, 249-259.[Medline]
Zou, Y. R., Kottmann, A. H., Kuroda, M., Taniuchi, I. & Littman, D. R. (1998). Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393, 595-599.[Medline]